Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pradigastat

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 1. Pradigastat is a potent and specific diacylglycerol acyltransferase-1 (DGAT1) inhibitor effective in lowering… Expand
2016
2016
Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, has activity in common metabolic diseases associated with… Expand
2016
2016
The DGAT1 inhibitor, pradigastat, demonstrated a mild phototoxicity signal in preclinical studies. Therefore, this clinical trial… Expand
2016
2016
Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To… Expand
Highly Cited
2015
Highly Cited
2015
BackgroundFamilial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2015
2015
Pradigastat is a potent and selective inhibitor of diacylglycerol acyltransferase 1, an enzyme highly expressed in the small… Expand
2015
2015
OBJECTIVE An in vitro drugdrug interaction (DDI) study was performed to assess the potential for pradigastat to inhibit breast… Expand
2015
2015
Background and ObjectivePradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, is under development to treat familial… Expand
  • table 1
  • figure 1
  • figure 2
  • table 3
  • figure 3
2014
2014
Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic… Expand